Image Source: Zacks Investment Research Spikevax, targeting the variant JN.1., is currently approved in the United States, the United Kingdom, Japan and Taiwan. Last month, the FDA approved ...

Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA ...

Moderna developed the Spikevax COVID-19 vaccine, and regulators approved this year its vaccine for RSV or respiratory syncytial virus. The company also has a combination flu/COVID vaccine and an ...

We apologize, but this video has failed to load. The mRNA vaccine, called Spikevax, has been reformulated to target the KP.2 subvariant of Omicron, the agency said. It replaces the previous ...

Until now, Canada has only had access to vaccine formulas that were approved in fall 2023 and target the Omicron XBB.1.5. Moderna's latest formulation of their mRNA vaccine, Spikevax, targets the KP.2 ...

Moderna laid out three priorities at its Investor Day. The first was to increase the usage of its Spikevax and mRESVIA vaccines. Spikevax is the company's current COVID vaccine, which was recently ...

Also included, are Comirnaty and Spikevax, both of which are approved for people 12 and older. Here's what else to know about about the updated vaccine. Anyone aged 6 months and older who got ...

Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based on messenger RNA - Moderna's Spikevax and Comirnaty, which is jointly developed by Pfizer ...

Kinney plans to open appointments for the Moderna (Spikevax) vaccine this week and will offer walk-in availability once enough inventory arrives. (People can sign up for alerts beforehand.) ...

The Food and Drug Administration approved a third, updated version of the COVID-19 vaccine from Pfizer and Moderna Thursday, and the vaccine could be released to the public in the coming days.

2 strain for 2024-25 COVID-19 vaccines. Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based on messenger RNA - Moderna's Spikevax and Comirnaty, ...